<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400777</url>
  </required_header>
  <id_info>
    <org_study_id>CVEA489ABR01</org_study_id>
    <nct_id>NCT00400777</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension</brief_title>
  <official_title>An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of the combination valsartan with&#xD;
      hydrochlorothiazide and amlodipine in hypertensive patients previously treated with valsartan&#xD;
      with hydrochlorothiazide and remaining uncontrolled. A naturalistic approach will be taken&#xD;
      comparing two different possible ways to achieve the higher dosage of the triple combination,&#xD;
      i.e. 160 mg of valsartan and 25 mg of hydrochlorothiazide with amlodipine 10 mg.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients reaching diastolic BP control, Proportion of patients reaching systolic BP control Percentage of diastolic responders,</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from study baseline in Diastolic Blood Pressure and in Systolic Blood Pressure after 4, 8 and 12 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from study baseline in standing diastolic and systolic blood pressure after 4, 8 and 12 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the valsartan/HCTZ/amlodipine treatment algorithm strategy after 4, 8 and 12 weeks of treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan, hydrochlorothiazide and amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≥18 years of age&#xD;
&#xD;
          -  Patients treated with up to two high blood pressure medications in a stable dose&#xD;
             considered adequate by the investigator, for a minimum of two months, with blood&#xD;
             pressure not controlled according to the following criteria:&#xD;
&#xD;
          -  Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg for low&#xD;
             risk patients (no known target organ damage and without risk factor or presenting 1 -&#xD;
             except Type 2 diabetes mellitus - risk factor);&#xD;
&#xD;
          -  Systolic Blood Pressure ≥130 and/or Diastolic Blood Pressure ≥85 mmHg for medium risk&#xD;
             patients (no known target organ damage and 2 or more risk factors - except Type 2&#xD;
             diabetes mellitus);&#xD;
&#xD;
          -  Systolic Blood Pressure ≥130 and/or Diastolic Blood Pressure ≥80 mmHg for high risk&#xD;
             patients (known target organ damage, and/or Type 2 diabetic patients and/or any&#xD;
             clinically identifiable cardiovascular disease). OR&#xD;
&#xD;
          -  Systolic Blood Pressure ≥160 mmHg and/or Diastolic Blood Pressure ≥100 mmHg at Visits&#xD;
             1 and 2 for previously untreated patients&#xD;
&#xD;
          -  Patients previously treated but who stopped their medications will be considered&#xD;
             untreated after one month without treatment&#xD;
&#xD;
          -  Obs: -The target organ are: Brain, Heart, Kidney, Retina.&#xD;
&#xD;
          -  The risk factors are: Smoking, Dyslipidemia, Age &gt; 60 years old, and Family history of&#xD;
             cardiovascular diseases (women &lt; 65 years old and men &lt; 55 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic Blood Pressure ≥180 mmHg and/or Diastolic Blood Pressure ≥110 mmHg at Visit 1&#xD;
             or Visit 2&#xD;
&#xD;
          -  Evidence of a secondary form of hypertension, to include coarctation of the aorta,&#xD;
             primary hyperaldosteronism, renal artery stenosis, or pheochromocytoma&#xD;
&#xD;
          -  Known Keith-Wagener grade III or IV hypertensive retinopathy&#xD;
&#xD;
          -  History of hypertensive encephalopathy&#xD;
&#xD;
          -  Cerebrovascular accident or myocardial infarction 12 months prior to Visit 1&#xD;
&#xD;
          -  History of transient ischemic attack 12 months prior to Visit 1&#xD;
&#xD;
          -  Percutaneous coronary intervention or coronary artery bypass graft surgery 12 months&#xD;
             prior to Visit 1&#xD;
&#xD;
          -  Diabetes mellitus type 1&#xD;
&#xD;
          -  Diabetes mellitus type 2 under insulin treatment&#xD;
&#xD;
          -  Poorly controlled type 2 diabetes mellitus&#xD;
&#xD;
          -  History of heart failure Grade II - IV according to the NYHA classification&#xD;
&#xD;
          -  Second or third degree heart block without a pacemaker&#xD;
&#xD;
          -  Concomitant unstable angina pectoris&#xD;
&#xD;
          -  Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia&#xD;
&#xD;
          -  Clinically significant valvular heart disease&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Any surgical or medical condition which, at the discretion of the investigator, place&#xD;
             the patient at higher risk from his/her participation in the study, or are likely to&#xD;
             prevent the patient from complying with the requirements of the study or completing&#xD;
             the trial period&#xD;
&#xD;
          -  Additional protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis AG</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>RJ 20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>June 17, 2008</last_update_submitted>
  <last_update_submitted_qc>June 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2008</last_update_posted>
  <keyword>Valsartan</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>amlodipine</keyword>
  <keyword>hypertension</keyword>
  <keyword>high blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

